Professor Martyn Caplin
BSc (Hons), DM, FRCP
Professor Martyn Caplin is Professor of Gastroenterology and Tumour Neuroendocrinology at the Royal Free Hospital and University College London. He leads the Royal Free Hospital European Neuroendocrine Tumor Society Centre of Excellence and the affiliated London WELLNET Unit.
He is chairman of the European Neuroendocrine Tumour Society and is the immediate past chairman of the National Cancer Research Institute Neuroendocrine Tumour Committee as well as immediate past chairman of the UK & Ireland Neuroendocrine Tumour Society. He has a large research programme investigating the effect of intestinal hormones on the gut as well as new diagnostic modalities and therapies for neuroendocrine tumours. He has been either chief investigator or principle investigator for many clinical trials. He has published over 150 research papers, written multiple book chapters and co-authored two books on neuroendocrine tumours. He regularly lectures both nationally and internationally as well as being a leading authority for pharmaceutical company advisory boards.
Between 2007 – 2012 he was the NHS clinical lead for the National Library for Health under the auspices of NICE for evidence based practice in Gastroenterology and Liver Diseases. Professor Caplin is also a consultant gastroenterologist at The Royal Free Hospital in North London.
Dr Daniel Krell
MBChB, BSc, MRCP, DPhil
Dr Daniel Krell undertook his oncology training at University College Hospital and The Royal Free Hospital in London. In addition to his primary medical degree, he also gained a Bachelor’s degree in immunology and microbiology, as well as a DPhil in Clinical Medicine at The University of Oxford.
Dr Krell’s DPhil research was undertaken at The University of Oxford’s, Wellcome Trust Centre for Human Genetics, and was funded by Cancer Research UK and HCA. Dr Krell’s research involved the design of models to investigate the role that genetic mutations in genes controlling cellular metabolism play in the development of cancer, with a view to identifying new therapeutic targets in this area. He continues to be involved in clinical research and clinical trials aimed at identifying new cancer therapies, with a focus on gastrointestinal, hepatobiliary and neuroendocrine tumours.
Dr Krell has published several peer-reviewed papers in journals such as Cancer Cell, The British Journal of Cancer and Lancet Oncology, and has submitted and presented abstracts and posters at national and international conferences.
Dr Krell is an integral member of the neuroendocrine tumour team at both the Wellington Hospital and The Royal Free Hospital where he works in collaboration with Professor Caplin, Dr Toumpanakis and their team at the NET MDT meetings and within the multi-disciplinary NET clinic.
His clinical work focuses on the management of patients with neuroendocrine tumours as well as gastro-oesophageal, colorectal, pancreatic, liver and bile duct cancers using chemotherapy, targeted therapy and immunotherapy.
He also manages patients with cancer of unknown primary and is the clinical lead at his institution for this. He also acts as the MDT lead for gastro-oesophageal and hepatobiliary cancer at his institution. He is a member of the chemotherapy operations group as well as the London cancer expert reference group for acute oncology and cancer of unknown primary.
T: 020 7317 2530
F: 020 7009 4230
Dr Christos Toumpanakis
Dr Christos Toumpanakis MD, PhD is a Consultant in Gastroenterology & Neuroendocrine Tumours in WELLNET and in the Neuroendocrine Tumour (NET) Unit – ENETS Centre of Excellence of Royal Free Hospital, London, UK. He is also an Honorary Senior Lecturer at University College London.
He graduated from Medical School-University of Athens in 1994, obtained his Specialty Title in Gastroenterology & Hepatology in 2004, and his PhD from University of Athens in 2007. He has been involved in the area of NETs since 2000. He has presented in several National & International Conferences, published many original papers and Reviews, and is considered as one of the leading UK experts in NETs.
He is a co-Author of UK & Ireland NET Guidelines and a member of the Advisory Board of the “UK NET patients’ foundation”. He is main interests include novel biomarkers and molecular imaging, mesenteric fibrosis, Peptide Receptor Radionuclide Therapy and carcinoid heart disease.